NO20091424L - Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav - Google Patents
Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse deravInfo
- Publication number
- NO20091424L NO20091424L NO20091424A NO20091424A NO20091424L NO 20091424 L NO20091424 L NO 20091424L NO 20091424 A NO20091424 A NO 20091424A NO 20091424 A NO20091424 A NO 20091424A NO 20091424 L NO20091424 L NO 20091424L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- substituted amides
- amides
- substituted
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84395906P | 2006-09-11 | 2006-09-11 | |
PCT/US2007/078181 WO2008033854A1 (en) | 2006-09-11 | 2007-09-11 | Certain substituted amides, method of making, and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091424L true NO20091424L (no) | 2009-06-10 |
Family
ID=38951317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091424A NO20091424L (no) | 2006-09-11 | 2009-04-07 | Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav |
Country Status (23)
Country | Link |
---|---|
US (1) | US8058446B2 (no) |
EP (1) | EP2081923B1 (no) |
JP (1) | JP5295961B2 (no) |
KR (1) | KR101442585B1 (no) |
CN (1) | CN101679361A (no) |
AR (1) | AR063706A1 (no) |
AU (1) | AU2007296559B2 (no) |
BR (1) | BRPI0716918A2 (no) |
CA (2) | CA2941688A1 (no) |
CL (1) | CL2007002640A1 (no) |
CO (1) | CO6160313A2 (no) |
CR (1) | CR10710A (no) |
EC (1) | ECSP099239A (no) |
ES (1) | ES2576478T3 (no) |
IL (1) | IL197230A0 (no) |
MA (1) | MA30782B1 (no) |
MX (1) | MX2009002649A (no) |
NO (1) | NO20091424L (no) |
PE (1) | PE20080839A1 (no) |
RU (1) | RU2009113693A (no) |
TW (1) | TW200829579A (no) |
WO (1) | WO2008033854A1 (no) |
ZA (1) | ZA200901633B (no) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
CN101835755B (zh) | 2007-10-23 | 2013-12-11 | 霍夫曼-拉罗奇有限公司 | 激酶抑制剂 |
US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
NZ588819A (en) | 2008-06-24 | 2012-08-31 | Hoffmann La Roche | 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives as inhibitors of Bruton's Tyrosine Kinase (Btk) |
CA2728683C (en) | 2008-07-02 | 2017-05-02 | F.Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CN103038233B (zh) * | 2010-05-07 | 2017-06-20 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
US8729072B2 (en) | 2011-11-03 | 2014-05-20 | F. Hoffman-La Roche Ag | Alkylated piperazine compounds |
KR20140096100A (ko) | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
CA2853967A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
EP2858982A4 (en) | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
GEP201706748B (en) | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
HUE031980T2 (en) | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
CA2912359A1 (en) | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
MX2016001480A (es) | 2013-07-30 | 2017-01-05 | Gilead Connecticut Inc | Formulacion de inhibidores de syk. |
PT3027618T (pt) | 2013-07-30 | 2020-10-12 | Kronos Bio Inc | Polimorfo de inibidores de syk |
CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
BR112016008593B1 (pt) * | 2013-10-18 | 2022-10-18 | Celgene Quanticel Research, Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso de um composto |
US9260415B2 (en) | 2013-12-05 | 2016-02-16 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
MX2016007346A (es) * | 2013-12-09 | 2016-09-13 | Abbvie Inc | Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio. |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA44075A (fr) * | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
KR102246124B1 (ko) | 2016-02-29 | 2021-04-30 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물 |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
WO2018053437A1 (en) | 2016-09-19 | 2018-03-22 | Mei Pharma, Inc. | Combination therapy |
KR102641030B1 (ko) | 2016-12-22 | 2024-02-29 | 인사이트 코포레이션 | Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체 |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
JP2020514384A (ja) | 2017-03-24 | 2020-05-21 | ジェネンテック, インコーポレイテッド | 自己免疫及び炎症性疾患を治療する方法 |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
EP3672974A1 (en) | 2017-08-25 | 2020-07-01 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
WO2019106146A1 (en) * | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
EP3492454A1 (en) * | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
EP3717459A1 (en) * | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
EP4212529A1 (en) | 2018-03-30 | 2023-07-19 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
FI3870574T3 (fi) | 2018-10-23 | 2023-04-03 | Step Pharma S A S | Aminopyrimidiini/pyratsiini-johdannaiset ctps1-inhibiittoreina |
CA3130848A1 (en) | 2019-02-22 | 2020-08-27 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
JP2002535318A (ja) * | 1999-01-22 | 2002-10-22 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2006053121A2 (en) * | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
EP1831168B1 (en) * | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
ES2543607T3 (es) | 2005-03-10 | 2015-08-20 | Gilead Connecticut, Inc. | Ciertas amidas sustituidas, método de obtención, y método de su uso |
US7786130B2 (en) * | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
US20100160292A1 (en) * | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
PE20081370A1 (es) * | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
-
2007
- 2007-09-10 PE PE2007001211A patent/PE20080839A1/es not_active Application Discontinuation
- 2007-09-10 AR ARP070103988A patent/AR063706A1/es unknown
- 2007-09-11 TW TW096133884A patent/TW200829579A/zh unknown
- 2007-09-11 BR BRPI0716918-3A patent/BRPI0716918A2/pt not_active Application Discontinuation
- 2007-09-11 WO PCT/US2007/078181 patent/WO2008033854A1/en active Application Filing
- 2007-09-11 KR KR1020097007477A patent/KR101442585B1/ko active IP Right Grant
- 2007-09-11 ES ES07842263.1T patent/ES2576478T3/es active Active
- 2007-09-11 US US11/853,485 patent/US8058446B2/en active Active
- 2007-09-11 AU AU2007296559A patent/AU2007296559B2/en not_active Ceased
- 2007-09-11 CL CL200702640A patent/CL2007002640A1/es unknown
- 2007-09-11 EP EP07842263.1A patent/EP2081923B1/en active Active
- 2007-09-11 CN CN200780041849A patent/CN101679361A/zh active Pending
- 2007-09-11 RU RU2009113693/04A patent/RU2009113693A/ru not_active Application Discontinuation
- 2007-09-11 JP JP2009527625A patent/JP5295961B2/ja active Active
- 2007-09-11 CA CA2941688A patent/CA2941688A1/en not_active Abandoned
- 2007-09-11 MX MX2009002649A patent/MX2009002649A/es not_active Application Discontinuation
- 2007-09-11 CA CA2661654A patent/CA2661654C/en not_active Expired - Fee Related
-
2009
- 2009-02-24 IL IL197230A patent/IL197230A0/en unknown
- 2009-03-06 ZA ZA200901633A patent/ZA200901633B/xx unknown
- 2009-03-31 CO CO09033014A patent/CO6160313A2/es unknown
- 2009-04-03 CR CR10710A patent/CR10710A/es not_active Application Discontinuation
- 2009-04-06 MA MA31766A patent/MA30782B1/fr unknown
- 2009-04-07 EC EC2009009239A patent/ECSP099239A/es unknown
- 2009-04-07 NO NO20091424A patent/NO20091424L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2661654A1 (en) | 2008-03-20 |
EP2081923B1 (en) | 2016-03-16 |
ES2576478T3 (es) | 2016-07-07 |
JP2010504287A (ja) | 2010-02-12 |
CA2941688A1 (en) | 2008-03-20 |
ECSP099239A (es) | 2009-07-31 |
JP5295961B2 (ja) | 2013-09-18 |
US8058446B2 (en) | 2011-11-15 |
EP2081923A1 (en) | 2009-07-29 |
AR063706A1 (es) | 2009-02-11 |
AU2007296559A1 (en) | 2008-03-20 |
MX2009002649A (es) | 2009-03-26 |
US20080139557A1 (en) | 2008-06-12 |
TW200829579A (en) | 2008-07-16 |
MA30782B1 (fr) | 2009-10-01 |
KR101442585B1 (ko) | 2014-10-02 |
CO6160313A2 (es) | 2010-05-20 |
BRPI0716918A2 (pt) | 2013-11-05 |
KR20090074762A (ko) | 2009-07-07 |
WO2008033854A1 (en) | 2008-03-20 |
AU2007296559B2 (en) | 2013-01-17 |
RU2009113693A (ru) | 2010-10-20 |
CN101679361A (zh) | 2010-03-24 |
ZA200901633B (en) | 2009-12-30 |
CR10710A (es) | 2009-07-14 |
CL2007002640A1 (es) | 2008-06-20 |
IL197230A0 (en) | 2009-12-24 |
CA2661654C (en) | 2016-10-11 |
PE20080839A1 (es) | 2008-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20091424L (no) | Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav | |
NO20091426L (no) | Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2252633T3 (da) | Anti-TrkA antistoffer og derivater deraf | |
IL185785A0 (en) | Certain substituted amides, method of making, and method of use thereof | |
DK2069352T3 (da) | Bestemte kemiske enheder, sammensætninger og fremgangsmåder | |
DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
DK3428148T3 (da) | Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf | |
BRPI0809573A8 (pt) | composição, e, método | |
DE602006020651D1 (de) | Kalibrierverfahren und -vorrichtung | |
DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
FI20060955A (fi) | Sakeutuslaite ja -menetelmä | |
DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
BRPI0614961A2 (pt) | aptâmero, método, e, composição | |
BRPI0814167A2 (pt) | Composição, e, método | |
DK1885716T3 (da) | Thiazolderivater og anvendelse deraf | |
DK1976884T3 (da) | Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf. | |
DE602006012689D1 (de) | Überprüfungsverfahren | |
NO20075424L (no) | Fremgangsmate og anvendelse | |
DK2310383T3 (da) | 2-oxo-alkyl-1-piperazin-2-onderivater, fremstilling deraf og terapeutisk anvendelse deraf | |
NO20073252L (no) | Fremgangsmate for kontinuerlig og proporsjonal kalktilsetting | |
DK2234966T3 (da) | Azetidinderivater, fremstilling og terapeutisk anvendelse heraf | |
NO344962B1 (no) | Amorf cesiumaluminiumfluorklompleks, dets fremstilling og bruk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |